Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
60 participants
INTERVENTIONAL
2024-11-07
2025-08-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
ESPB vs iPACK+ACB in Total Knee Arthroplasty
NCT06302218
Dexamethasone for iPACK Block With ACB in Total Knee Arthroplasty
NCT06470204
Dexamethasone Vs. Dexmedetomidine for ESPB in Pain Management After Knee Arthroplasty
NCT06470100
iPACK Block for Total Knee Arthroplasty
NCT06087562
Periarticular Injection and Hamstring Block Versus Placebo for Pain Control in Anterior Cruciate Ligament Reconstruction
NCT05248724
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
iPACK + ACB
Ultrasound-guided iPACK +ACB
2 x 20 ml of Ropivacaine 0.2% Injectable Solution
2 x 20ml 0.2% Ropivacaine - ultrasound-guided iPACK + ACB
Two-Level ESPB
Bi-level Ultrasound-guided ESPB et the L1 and S1
2 x 20ml of Ropivacaine 0.2% Injectable Solution
2 x 20ml 0.2% ropivacaine - ultrasound-guided ESPB at the L1 and S1 level
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
2 x 20 ml of Ropivacaine 0.2% Injectable Solution
2 x 20ml 0.2% Ropivacaine - ultrasound-guided iPACK + ACB
2 x 20ml of Ropivacaine 0.2% Injectable Solution
2 x 20ml 0.2% ropivacaine - ultrasound-guided ESPB at the L1 and S1 level
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients aged \>65 and \<100 years
* patients able to provide informed consent
* patients able to reliably report symptoms to the research team
Exclusion Criteria
65 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Poznan University of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Malgorzata Reysner, M.D. Ph.D.
Role: STUDY_CHAIR
Poznań University of Medical Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Poznan University of Medical Sciences
Poznan, Poznań, Poland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
9/2024
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.